Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Serotonin Transporter (SERT) S2 allosteric site is a secondary binding pocket located in the extracellular vestibule of the SLC6A4 protein, distinct from the primary orthosteric (S1) site where serotonin binds (UniProt P31645). This site plays a crucial role in modulating the transport kinetics of the protein by influencing the affinity and dissociation rates of ligands bound at the S1 site (Chen et al., 2005). When a molecule, such as the antidepressant escitalopram, binds to the S2 site, it acts as an allosteric modulator that sterically traps the ligand in the S1 site, effectively prolonging the inhibition of serotonin reuptake (Plenge et al., 2007). This mechanism is significant in the treatment of major depressive disorder and anxiety, as it enhances the potency and duration of action of certain selective serotonin reuptake inhibitors (SSRIs) (StatPearls, 2023). Understanding the S2 site has led to the classification of "allosteric SSRIs," which offer distinct pharmacological profiles compared to traditional orthosteric inhibitors (Coleman et al., 2016). Research into this site continues to inform the development of more effective neuropsychiatric medications with potentially fewer side effects by targeting specific conformational states of the transporter. The S2 site's discovery has provided a structural basis for the high affinity and slow dissociation of escitalopram, distinguishing it from its R-enantiomer and other SSRIs (Zhong et al., 2012). Therapeutic targeting of this site represents a sophisticated approach to fine-tuning neurotransmitter homeostasis in the central nervous system.
Allosteric inhibition of serotonin transport by stabilizing the inhibitor-bound state at the orthosteric site through steric hindrance at the extracellular vestibule, thereby decreasing the dissociation rate of the primary inhibitor.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin transporter (SERT) S2 allosteric site (SERT S2 site).